<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00382863</url>
  </required_header>
  <id_info>
    <org_study_id>200</org_study_id>
    <nct_id>NCT00382863</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial</brief_title>
  <acronym>PEERLESS-HF</acronym>
  <official_title>Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paracor Medical, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Paracor Medical, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if patients in the HeartNet Ventricular Support
      System with optimal medical and device therapy arm (Treatment group) show statistically
      significant improvement compared to patients in the optimal medical and device therapy alone
      arm (Control group) after 6 months of follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the United States alone, more than five million people suffer from heart failure (CHF) and
      an estimated 400,000 to 700,000 new cases are diagnosed each year. Caused by a variety of
      cardiac conditions, systolic heart failire (HF) is the end-stage of heart disease where the
      heart is failing as a pump. Once diagnosed with the disease, less than 50% of the patients
      live for five years, and less than 25% survive for more than ten years. The number of deaths
      in the United States from this condition has more than doubled since 1979, averaging more
      than 250,000 annually.

      Paracor Medical, Inc. has developed an elastic prosthetic wrap that is designed to apply a
      gentle mechanical support to the failing heart. The Implant is a compliant elastic structure
      that is designed to conform to the epicardial surface of the right and left ventricles. It
      supports the heart throughout the cardiac cycle and was designed to offload the ventricles
      and reduce wall stress.

      The objective of this clinical trial is to evaluate the safety and efficacy of the HeartNet
      Ventricular Support System with optimal medical and device therapy (Treatment group) when
      compared to optimal medical and device therapy (i.e., medications, cardiac resynchronisation
      therapy, pacemaker) alone (Control group) as treatments for patients with heart failure.

      Efficacy of the HeartNet Ventricular Support System in the Treatment group compared to the
      optimal medical and device therapy Control group will be evaluated based upon cardiopulmonary
      tests (Peak VO2), six (6) minute walk distance and quality of life assessment, as measured by
      the Minnesota Living with Heart Failure (MLWHF) questionnaire.

      Safety of the HeartNet Ventricular Support System in the Treatment group compared to the
      Control group will be evaluated based on the all-cause mortality rate.

      Paracor Medical intends to submit data obtained in this clinical trial to support a
      Pre-Market Approval Application to the United States Food and Drug Administration.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Resources unavailable to continue study follow-up.
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder Analysis - Peak Oxygen Uptake (Peak VO2)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>A participant was considered a &quot;responder&quot; if cardiopulmonary exercise testing demonstrated an improvement in peak VO2 of at least 1.0 ml/kg/min at 6 months as compared to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder Analysis - Six (6) Minute Walk (6MW) Distance</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>A participant was considered a &quot;responder&quot; if 6MW distance at 6 months was at least 45 meters more than at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder Analysis - Minnesota Living With Heart Failure (MLWHF) Quality of Life Overall Score</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>A participant was considered a &quot;responder&quot; if the MLHF overall score had improved by at least 7 points at 6 months as compared to baseline. THE MLHF questionnaire evaluates the impact of heart failure (HF) on a subject's physical, emotional, social and mental aspects of quality of life. Each of 21 questions about how much HF impacts daily activities is scored from 0-no impact to 5-very much (overall score can range from 0 to 105). Improvement is indicated by a decrease in score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participant Deaths</measure>
    <time_frame>12 months</time_frame>
    <description>Total number of participants who died within 12 months of enrollment into the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association (NYHA) Functional Class</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Change in NYHA functional class between baseline and 6 months. &quot;Maintained&quot; means the participant's functional class remained the same as baseline. &quot;Improved&quot; means the participant's functional class improved (became lower in number) by at least one class. &quot;Worsened&quot; means the participant's functional class deteriorated (became higher in number) by at least one class.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>The KCCQ is a 23-item questionnaire that quantifies physical function, symptoms, social function, self-efficacy/knowledge and quality of life. Scores range from 0 to 100, where higher scores reflect better health status. For this outcome measure, the difference between each participant's baseline and 6-month KCCQ scores was calculated. The mean change for each treatment arm is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Mass</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular mass was calculated. The median change for each treatment arm is presented. A decrease in mass is associated with an improvement in the participant's structural heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Analysis - Peak Oxygen Uptake (Peak VO2)</measure>
    <time_frame>baseline to 12 months</time_frame>
    <description>A participant was considered a &quot;responder&quot; if cardiopulmonary exercise testing demonstrated an improvement in peak VO2 of at least 1.0 ml/kg/min at 12 months as compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Analysis - Six (6) Minute Walk (6MW) Distance</measure>
    <time_frame>baseline to 12 Months</time_frame>
    <description>A participant was considered a &quot;responder&quot; if 6MW distance at 12 months was at least 45 meters more than at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Analysis - Minnesota Living With Heart Failure (MLWHF) Quality of Life Overall Score</measure>
    <time_frame>baseline to 12 months</time_frame>
    <description>A participant was considered a &quot;responder&quot; if the MLHF overall score had improved by at least 7 points at 12 months as compared to baseline. THE MLHF questionnaire evaluates the impact of heart failure (HF) on a subject's physical, emotional, social and mental aspects of quality of life. Each of 21 questions about how much HF impacts daily activities is scored from 0-no impact to 5-very much (overall score can range from 0 to 105). Improvement is indicated by a decrease in score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Hospitalization - Actuarial Analysis</measure>
    <time_frame>12 months</time_frame>
    <description>Kaplan-Meier actuarial analysis of heart failure hospitalization (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular End Diastolic Volume</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end diastolic volume was calculated. The median change for each treatment arm is presented. A decrease in volume is associated with an improvement in the participant's structural heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular End Systolic Volume</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end systolic volume was calculated. The median change for each treatment arm is presented. A decrease in volume indicates an improvement in the participant's structural heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ejection Fraction</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular ejection fraction was calculated. The median change for each treatment arm is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular End Diastolic Diameter</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end diastolic diameter was calculated. The median change for each treatment arm is presented. A decrease in diameter indicates an improvement in the participant's structural heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular End Systolic Diameter</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end systolic diameter was calculated. The median change for each treatment arm is presented. A decrease in diameter indicates an improvement in the participant's structural heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success (Number of Treatment Arm Participants Successfully Implanted)</measure>
    <time_frame>1 day</time_frame>
    <description>&quot;Technical success&quot; refers to the ability to successfully deliver a device onto the epicardial surface and leave the device in a satisfactory position. Participants who did not undergo an implant procedure were excluded from this analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Death</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants who died within 12 months of enrolling in the study and whose cause of death was classified, by an independent Clinical Events Committee, as heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Death - Actuarial Analysis</measure>
    <time_frame>12 months</time_frame>
    <description>Kaplan-Meier actuarial time-to-event analysis of deaths classified, by an independent Clinical Events Committee, as due to heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants who experienced a heart failure hospitaliz (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-Cause Hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants who experienced a hospitalization (for any cause) within the first 12 months after enrollment. Within the Treatment Arm, hospitalization for the implant procedure was not included in this analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-Cause Hospitalization - Actuarial Analysis</measure>
    <time_frame>12 months</time_frame>
    <description>Kaplan-Meier actuarial time-to-first-event analysis of all-cause hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Experiencing Serious Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants who experienced a serious adverse event (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events - Actuarial Analysis</measure>
    <time_frame>12 months</time_frame>
    <description>Kaplan-Meier actuarial time-to-first-event analysis of serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Alive Out of Hospital</measure>
    <time_frame>12 months</time_frame>
    <description>Median number of days participants were not hospitalized within the first 12 months after enrollment. Within the Treatment Arm, hospitalization for the implant procedure was not included in this analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HeartNet and Optimal Medical/Device Therapy (e.g., medications and cardiac resynchronisation therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal Medical/Device Therapy alone (e.g., medications and/or cardiac resynchronisation therapy) (Note: For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of angiotensin converting enzyme (ACE) inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy-defibrillator (CRT-D) for at least three months prior to study enrollment, when indicated.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeartNet Ventricular Support System</intervention_name>
    <description>The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>cardiac support</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimal Medical/Device Therapy</intervention_name>
    <description>Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>heart failure medications</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Symptomatic heart failure at enrollment (American College of Cardiology [ACC]/American
             Heart Association [AHA] Stage C) due to ischemic or nonischemic dilated cardiomyopathy

          2. On stable, evidence-based medical and device therapy for heart failure for 3 months
             prior to randomization &lt;a&gt; Pharmacological Therapy (as appropriate) &lt;i&gt; angiotensin
             converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) for
             patients with ACE inhibitor intolerance or nitrate/hydralazine at the investigators
             discretion &lt;ii&gt; beta blockers &lt;iii&gt; diuretics, aldosterone inhibitors &lt;b&gt; Ejection
             fraction &lt; or = to 35% while maintained on optimal medical therapy &lt;c&gt; Cardiac
             Resynchronization Therapy (CRT), Cardiac Resynchronization Therapy-Defibrillator
             (CRT-D) &lt;i&gt; If implanted with a CRT or CRT-D, it must be implanted &gt; or = to 3 months
             before randomization &lt;ii&gt; If currently eligible or anticipated eligibility with a CRT
             or CRT-D within 6 months, the patient should not be enrolled in the study

        Specific Qualifying Characteristics

          1. Six (6) minute walk of 150 - 450m

          2. Peak VO2 for males: 10.0-20.0 ml/kg/min; Peak VO2 for females: 9.0-18.0 ml/kg/min

          3. Left ventricular end diastolic diameter (LVEDD) &lt;85mm and index &lt;40mm/m2 (LVEDD/BSA)

          4. Heart failure duration &gt; or = to 6 months

        Exclusion Criteria:

        Patient History

          1. Heart failure due to a reversible condition

          2. Hypertrophic obstructive cardiomyopathy (HOCM)

          3. Left ventricular assist device (LVAD), intra-aortic balloon pump (IABP) or intravenous
             inotropes are required or the patient has end stage heart failure despite maintenance
             on best medical therapy

          4. Myxoma

          5. Active infection, sepsis, endocarditis, myocarditis or pericarditis

          6. Myocardial infarction, stroke, transient ischemic attack, cardiac or other major
             surgery, or implantable cardioverter defibrillator (ICD) or pacemaker implantation in
             the 3 months prior to entry

          7. Positive pregnancy test for pre-menopausal female

          8. Less than 18 years or &gt; or = to 75 years old

          9. Hemoglobin level less than 10 gm/dL or creatinine &gt;2.5 mg/dL

         10. Uncontrolled medical conditions that increase surgical risk

         11. Co-morbid condition that in the investigator's opinion reduces life expectancy to less
             than 2 years

        Surgical or Anatomical Considerations

          1. Heart measurement too large or small for Implant sizes

          2. Restrictive cardiomyopathy

          3. Not a candidate for sternotomy or standard thoracotomy surgical approaches

          4. Expected to have adhesions from previous surgical procedures

          5. History of constrictive pericarditis

          6. Previously placed coronary artery bypass grafts (CABG) or anticipated need for
             coronary artery bypass grafting

          7. Not a candidate for cardiopulmonary bypass

          8. Anatomical mitral valve regurgitation of 2+ or greater at the time of enrollment

          9. Pulmonary function testing with the following results: Forced expiratory volume (FEV1)
             &lt;1L or if FEV1 is between 1 and 3L, forced expiratory volume divided by forced vital
             capacity (FEV1/FVC) &lt;60%

         10. Cardiac or thoracic condition that might require operative correction. Cardiac
             transplantation is not included in this exclusion criterion.

         11. Other elective surgical procedure at the time of the index hospitalization or within
             30 days, whichever is longer

        Other

          1. Any other medical condition that, in the judgment of the investigator, makes the
             patient a poor candidate for this procedure

          2. Currently enrolled or has participated in the last 30 days in another therapeutic or
             interventional clinical study

          3. Unwilling/unable to comply with follow-up

          4. Unwilling/unable to give signed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William T. Abraham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief, Division of Cardiovascular Medicine, The Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco, Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Heart Foundation</name>
      <address>
        <city>Lombard</city>
        <state>Illinois</state>
        <zip>60148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital and Health Services</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Medical Center</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Division of Cardiology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas St. Elizabeth's Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/ Oakwood Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul Heart Clinic</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BryanLGH Heart Improvement Program</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Clinical Trial Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Stern Cardiovascular Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Cardiovascular Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Heart &amp; Vascular Institute/ Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Hospital Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2006</study_first_submitted>
  <study_first_submitted_qc>September 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2006</study_first_posted>
  <results_first_submitted>May 13, 2011</results_first_submitted>
  <results_first_submitted_qc>June 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 13, 2012</results_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>cardiac support</keyword>
  <keyword>Paracor</keyword>
  <keyword>HeartNet</keyword>
  <keyword>PEERLESS-HF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 29 investigational sites in the US and 6 investigational sites in Canada, between November, 2006 to September, 2009</recruitment_details>
      <pre_assignment_details>3 subjects were considered Roll-in (not randomized) and received treatment. Data from these subjects are not included in the results. Seven (7) subjects were randomized to the Treatment group but were not treated due to suspension of the study. These subjects are excluded from the data.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>HeartNet and Optimal Medical/Device Therapy</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Optimal Medical/Device Therapy alone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>HeartNet and Optimal Medical/Device Therapy</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Optimal Medical/Device Therapy alone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
            <count group_id="B2" value="114"/>
            <count group_id="B3" value="210"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.1" spread="10.2"/>
                    <measurement group_id="B2" value="54.5" spread="10.8"/>
                    <measurement group_id="B3" value="54.8" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Self-reported race. Since the participants were allowed to select more than one race, the sum of races is greater than the number of participants in each group.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association (NYHA) Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>NYHA I: Pts w/cardiac disease, w/o activity limit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA II; Pts w/cardiac disease, slight limits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA III; Marked limit to physical activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA IV; inability to have activity w/o discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Failure Etiology</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-ischemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ischemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Heart Failure (time)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="6.2"/>
                    <measurement group_id="B2" value="6.5" spread="5.0"/>
                    <measurement group_id="B3" value="7.1" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac Medications</title>
          <description>Baseline information for specific cardiac medications was requested. Since most participants were on more than one medication, the sum of medications are greater than the number of participants in each group.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ACE Inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antiogensin Receptor Blockers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diuretics (other than Spironolactone)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digoxin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical History and Co-Morbidities</title>
          <description>Baseline information on specific co-morbities was requested. Since many participants had more than one co-morbidity, the sum of co-morbidities are greater than the number of participants in each group.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Systemic Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Obstructive Pulmonary Disease (COPD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Apnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coronary Artery Disease with Angioplasty/Stent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke TIA/Other Thromboembolic Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral Vascular Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular Tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial Fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biventricular Pacemaker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biventricular ICD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacemaker alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICD alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICD with Bradycardia Pacing Capability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Responder Analysis - Peak Oxygen Uptake (Peak VO2)</title>
        <description>A participant was considered a &quot;responder&quot; if cardiopulmonary exercise testing demonstrated an improvement in peak VO2 of at least 1.0 ml/kg/min at 6 months as compared to baseline.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>The population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Analysis - Peak Oxygen Uptake (Peak VO2)</title>
          <description>A participant was considered a &quot;responder&quot; if cardiopulmonary exercise testing demonstrated an improvement in peak VO2 of at least 1.0 ml/kg/min at 6 months as compared to baseline.</description>
          <population>The population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis = proportion of subjects in treatment group who successfully achieved an improvement of at least 1.0 ml/kg/min at 6 months is less than or equal to the Control group. Subjects who withdrew for cardiac-related reasons were classified as non-responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.502</p_value>
            <method>Fisher Exact</method>
            <method_desc>One-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Responder Analysis - Six (6) Minute Walk (6MW) Distance</title>
        <description>A participant was considered a &quot;responder&quot; if 6MW distance at 6 months was at least 45 meters more than at baseline.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>The population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Analysis - Six (6) Minute Walk (6MW) Distance</title>
          <description>A participant was considered a &quot;responder&quot; if 6MW distance at 6 months was at least 45 meters more than at baseline.</description>
          <population>The population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis = the proportion of subjects in the treatment group who successfully achieved an improvement of at least 45 m at 6 months from baseline is less than or equal to that of the Control group. Withdrawals due to cardiac reasons are counted as non-responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>Fisher Exact</method>
            <method_desc>One-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Responder Analysis - Minnesota Living With Heart Failure (MLWHF) Quality of Life Overall Score</title>
        <description>A participant was considered a &quot;responder&quot; if the MLHF overall score had improved by at least 7 points at 6 months as compared to baseline. THE MLHF questionnaire evaluates the impact of heart failure (HF) on a subject's physical, emotional, social and mental aspects of quality of life. Each of 21 questions about how much HF impacts daily activities is scored from 0-no impact to 5-very much (overall score can range from 0 to 105). Improvement is indicated by a decrease in score.</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>The population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Analysis - Minnesota Living With Heart Failure (MLWHF) Quality of Life Overall Score</title>
          <description>A participant was considered a &quot;responder&quot; if the MLHF overall score had improved by at least 7 points at 6 months as compared to baseline. THE MLHF questionnaire evaluates the impact of heart failure (HF) on a subject's physical, emotional, social and mental aspects of quality of life. Each of 21 questions about how much HF impacts daily activities is scored from 0-no impact to 5-very much (overall score can range from 0 to 105). Improvement is indicated by a decrease in score.</description>
          <population>The population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis = the proportion of treatment subjects who successfully achieved an improvement of at least 7 points at 6 months is equal to or less than that of the control group. Withdrawals due to cardiac reasons are counted as non-responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.184</p_value>
            <method>Fisher Exact</method>
            <method_desc>One-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participant Deaths</title>
        <description>Total number of participants who died within 12 months of enrollment into the trial.</description>
        <time_frame>12 months</time_frame>
        <population>The population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant Deaths</title>
          <description>Total number of participants who died within 12 months of enrollment into the trial.</description>
          <population>The population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis = survival in the treatment group at 12 months is not equivalent to that of the Control group.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Estimated survival for the treatment group was 93%. Estimated survival for the control group was 91.5%. A non-inferiority margin of 7.5%. Final test alpha level of 0.04825.</non_inferiority_desc>
            <p_value>0.012</p_value>
            <method>Exact binomial test</method>
            <method_desc>One-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in New York Heart Association (NYHA) Functional Class</title>
        <description>Change in NYHA functional class between baseline and 6 months. &quot;Maintained&quot; means the participant's functional class remained the same as baseline. &quot;Improved&quot; means the participant's functional class improved (became lower in number) by at least one class. &quot;Worsened&quot; means the participant's functional class deteriorated (became higher in number) by at least one class.</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in New York Heart Association (NYHA) Functional Class</title>
          <description>Change in NYHA functional class between baseline and 6 months. &quot;Maintained&quot; means the participant's functional class remained the same as baseline. &quot;Improved&quot; means the participant's functional class improved (became lower in number) by at least one class. &quot;Worsened&quot; means the participant's functional class deteriorated (became higher in number) by at least one class.</description>
          <population>Population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintained</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Class change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
        <description>The KCCQ is a 23-item questionnaire that quantifies physical function, symptoms, social function, self-efficacy/knowledge and quality of life. Scores range from 0 to 100, where higher scores reflect better health status. For this outcome measure, the difference between each participant's baseline and 6-month KCCQ scores was calculated. The mean change for each treatment arm is presented.</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Population is intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
          <description>The KCCQ is a 23-item questionnaire that quantifies physical function, symptoms, social function, self-efficacy/knowledge and quality of life. Scores range from 0 to 100, where higher scores reflect better health status. For this outcome measure, the difference between each participant's baseline and 6-month KCCQ scores was calculated. The mean change for each treatment arm is presented.</description>
          <population>Population is intent to treat</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="18.2"/>
                    <measurement group_id="O2" value="3.4" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Mass</title>
        <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular mass was calculated. The median change for each treatment arm is presented. A decrease in mass is associated with an improvement in the participant's structural heart failure.</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Mass</title>
          <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular mass was calculated. The median change for each treatment arm is presented. A decrease in mass is associated with an improvement in the participant's structural heart failure.</description>
          <population>Population is intent to treat.</population>
          <units>grams</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.0" lower_limit="-119.0" upper_limit="81.0"/>
                    <measurement group_id="O2" value="7.0" lower_limit="-254.0" upper_limit="109.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Two-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Analysis - Peak Oxygen Uptake (Peak VO2)</title>
        <description>A participant was considered a &quot;responder&quot; if cardiopulmonary exercise testing demonstrated an improvement in peak VO2 of at least 1.0 ml/kg/min at 12 months as compared to baseline.</description>
        <time_frame>baseline to 12 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Analysis - Peak Oxygen Uptake (Peak VO2)</title>
          <description>A participant was considered a &quot;responder&quot; if cardiopulmonary exercise testing demonstrated an improvement in peak VO2 of at least 1.0 ml/kg/min at 12 months as compared to baseline.</description>
          <population>Population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Improvement of at least 1.0 ml/kg/min from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.540</p_value>
            <method>Fisher Exact</method>
            <method_desc>One-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Analysis - Six (6) Minute Walk (6MW) Distance</title>
        <description>A participant was considered a &quot;responder&quot; if 6MW distance at 12 months was at least 45 meters more than at baseline.</description>
        <time_frame>baseline to 12 Months</time_frame>
        <population>Population is intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Analysis - Six (6) Minute Walk (6MW) Distance</title>
          <description>A participant was considered a &quot;responder&quot; if 6MW distance at 12 months was at least 45 meters more than at baseline.</description>
          <population>Population is intent to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Improvement of at least 45 m from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.067</p_value>
            <method>Fisher Exact</method>
            <method_desc>One-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Analysis - Minnesota Living With Heart Failure (MLWHF) Quality of Life Overall Score</title>
        <description>A participant was considered a &quot;responder&quot; if the MLHF overall score had improved by at least 7 points at 12 months as compared to baseline. THE MLHF questionnaire evaluates the impact of heart failure (HF) on a subject's physical, emotional, social and mental aspects of quality of life. Each of 21 questions about how much HF impacts daily activities is scored from 0-no impact to 5-very much (overall score can range from 0 to 105). Improvement is indicated by a decrease in score.</description>
        <time_frame>baseline to 12 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Analysis - Minnesota Living With Heart Failure (MLWHF) Quality of Life Overall Score</title>
          <description>A participant was considered a &quot;responder&quot; if the MLHF overall score had improved by at least 7 points at 12 months as compared to baseline. THE MLHF questionnaire evaluates the impact of heart failure (HF) on a subject's physical, emotional, social and mental aspects of quality of life. Each of 21 questions about how much HF impacts daily activities is scored from 0-no impact to 5-very much (overall score can range from 0 to 105). Improvement is indicated by a decrease in score.</description>
          <population>Population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Improvement of at least 7 points from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Fisher Exact</method>
            <method_desc>One-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Failure Hospitalization - Actuarial Analysis</title>
        <description>Kaplan-Meier actuarial analysis of heart failure hospitalization (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment</description>
        <time_frame>12 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Failure Hospitalization - Actuarial Analysis</title>
          <description>Kaplan-Meier actuarial analysis of heart failure hospitalization (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment</description>
          <population>Population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier actuarial time-to-first-event analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.109</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular End Diastolic Volume</title>
        <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end diastolic volume was calculated. The median change for each treatment arm is presented. A decrease in volume is associated with an improvement in the participant's structural heart failure.</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End Diastolic Volume</title>
          <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end diastolic volume was calculated. The median change for each treatment arm is presented. A decrease in volume is associated with an improvement in the participant's structural heart failure.</description>
          <population>Population is intent to treat.</population>
          <units>milliliters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" lower_limit="-108.1" upper_limit="127.5"/>
                    <measurement group_id="O2" value="10.9" lower_limit="-143.7" upper_limit="176.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Two-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular End Systolic Volume</title>
        <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end systolic volume was calculated. The median change for each treatment arm is presented. A decrease in volume indicates an improvement in the participant's structural heart failure.</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End Systolic Volume</title>
          <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end systolic volume was calculated. The median change for each treatment arm is presented. A decrease in volume indicates an improvement in the participant's structural heart failure.</description>
          <population>Population is intent to treat.</population>
          <units>milliliters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" lower_limit="-100.5" upper_limit="125.0"/>
                    <measurement group_id="O2" value="2.75" lower_limit="-134.2" upper_limit="150.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.179</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Two-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ejection Fraction</title>
        <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular ejection fraction was calculated. The median change for each treatment arm is presented.</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ejection Fraction</title>
          <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular ejection fraction was calculated. The median change for each treatment arm is presented.</description>
          <population>Population is intent to treat.</population>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-11.0" upper_limit="16.0"/>
                    <measurement group_id="O2" value="1.9" lower_limit="-18.0" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Two-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular End Diastolic Diameter</title>
        <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end diastolic diameter was calculated. The median change for each treatment arm is presented. A decrease in diameter indicates an improvement in the participant's structural heart failure.</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End Diastolic Diameter</title>
          <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end diastolic diameter was calculated. The median change for each treatment arm is presented. A decrease in diameter indicates an improvement in the participant's structural heart failure.</description>
          <population>Population is intent to treat.</population>
          <units>centimeters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" lower_limit="-1.2" upper_limit="1.7"/>
                    <measurement group_id="O2" value="0" lower_limit="-1.3" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Two-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular End Systolic Diameter</title>
        <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end systolic diameter was calculated. The median change for each treatment arm is presented. A decrease in diameter indicates an improvement in the participant's structural heart failure.</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End Systolic Diameter</title>
          <description>The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end systolic diameter was calculated. The median change for each treatment arm is presented. A decrease in diameter indicates an improvement in the participant's structural heart failure.</description>
          <population>Population is intent to treat.</population>
          <units>centimeters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-1.2" upper_limit="2.1"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-1.8" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Two-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technical Success (Number of Treatment Arm Participants Successfully Implanted)</title>
        <description>&quot;Technical success&quot; refers to the ability to successfully deliver a device onto the epicardial surface and leave the device in a satisfactory position. Participants who did not undergo an implant procedure were excluded from this analysis.</description>
        <time_frame>1 day</time_frame>
        <population>Population is as treated, treatment only.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success (Number of Treatment Arm Participants Successfully Implanted)</title>
          <description>&quot;Technical success&quot; refers to the ability to successfully deliver a device onto the epicardial surface and leave the device in a satisfactory position. Participants who did not undergo an implant procedure were excluded from this analysis.</description>
          <population>Population is as treated, treatment only.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Failure Death</title>
        <description>Number of participants who died within 12 months of enrolling in the study and whose cause of death was classified, by an independent Clinical Events Committee, as heart failure</description>
        <time_frame>12 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Failure Death</title>
          <description>Number of participants who died within 12 months of enrolling in the study and whose cause of death was classified, by an independent Clinical Events Committee, as heart failure</description>
          <population>Population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.627</p_value>
            <method>Fisher Exact</method>
            <method_desc>Two-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Failure Death - Actuarial Analysis</title>
        <description>Kaplan-Meier actuarial time-to-event analysis of deaths classified, by an independent Clinical Events Committee, as due to heart failure</description>
        <time_frame>12 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Failure Death - Actuarial Analysis</title>
          <description>Kaplan-Meier actuarial time-to-event analysis of deaths classified, by an independent Clinical Events Committee, as due to heart failure</description>
          <population>Population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.386</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Failure Hospitalization</title>
        <description>Number of participants who experienced a heart failure hospitaliz (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment.</description>
        <time_frame>12 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Failure Hospitalization</title>
          <description>Number of participants who experienced a heart failure hospitaliz (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment.</description>
          <population>Population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.154</p_value>
            <method>Fisher Exact</method>
            <method_desc>Two-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-Cause Hospitalization</title>
        <description>Number of participants who experienced a hospitalization (for any cause) within the first 12 months after enrollment. Within the Treatment Arm, hospitalization for the implant procedure was not included in this analysis.</description>
        <time_frame>12 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>All-Cause Hospitalization</title>
          <description>Number of participants who experienced a hospitalization (for any cause) within the first 12 months after enrollment. Within the Treatment Arm, hospitalization for the implant procedure was not included in this analysis.</description>
          <population>Population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
            <method_desc>Two-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-Cause Hospitalization - Actuarial Analysis</title>
        <description>Kaplan-Meier actuarial time-to-first-event analysis of all-cause hospitalizations</description>
        <time_frame>12 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>All-Cause Hospitalization - Actuarial Analysis</title>
          <description>Kaplan-Meier actuarial time-to-first-event analysis of all-cause hospitalizations</description>
          <population>Population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.939</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Experiencing Serious Adverse Events</title>
        <description>Number of participants who experienced a serious adverse event (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment</description>
        <time_frame>12 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Experiencing Serious Adverse Events</title>
          <description>Number of participants who experienced a serious adverse event (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment</description>
          <population>Population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Fisher Exact</method>
            <method_desc>Two-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events - Actuarial Analysis</title>
        <description>Kaplan-Meier actuarial time-to-first-event analysis of serious adverse events</description>
        <time_frame>12 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events - Actuarial Analysis</title>
          <description>Kaplan-Meier actuarial time-to-first-event analysis of serious adverse events</description>
          <population>Population is intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Alive Out of Hospital</title>
        <description>Median number of days participants were not hospitalized within the first 12 months after enrollment. Within the Treatment Arm, hospitalization for the implant procedure was not included in this analysis.</description>
        <time_frame>12 months</time_frame>
        <population>Population is intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>HeartNet and Optimal Medical/Device Therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal Medical/Device Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Days Alive Out of Hospital</title>
          <description>Median number of days participants were not hospitalized within the first 12 months after enrollment. Within the Treatment Arm, hospitalization for the implant procedure was not included in this analysis.</description>
          <population>Population is intent to treat.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365" lower_limit="45" upper_limit="365"/>
                    <measurement group_id="O2" value="365" lower_limit="149" upper_limit="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.772</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Two-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed up to 3.5 years</time_frame>
      <desc>Events adjudicated per Clinical Events Committee (CEC) Charter by independent CEC.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>HeartNet and Optimal Medical/Device Therapy</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Optimal Medical/Device Therapy alone</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Heart Failure</sub_title>
                <description>Non-perioperative</description>
                <counts group_id="E1" events="42" subjects_affected="15" subjects_at_risk="96"/>
                <counts group_id="E2" events="46" subjects_affected="27" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Non-Ischemic Atrial/Ventricular Dysrhythmia</sub_title>
                <description>Non-perioperative</description>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cardiac Procedure</sub_title>
                <description>Non-perioperative</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Other Cardiac Hospitalization</sub_title>
                <description>Non-perioperative</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Non-perioperative</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Myocardial Infarct</sub_title>
                <description>Non-perioperative</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Coronary Insufficiency/Acute Coronary Syndrome/Unstable Angina</sub_title>
                <description>Non-perioperative</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Arrythmias</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pericardial Syndrome</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Blood Loss</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Worsening Heart Failure</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>LV Laceration</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Chest Pain Syndrome</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroesophageal Reflux</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Bleeding</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac/Non-vascular</sub_title>
                <description>Non-perioperative</description>
                <counts group_id="E1" events="32" subjects_affected="22" subjects_at_risk="96"/>
                <counts group_id="E2" events="36" subjects_affected="24" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Laryngeal Granuloma</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Alcohol Withdrawal</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia/Sepsis</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure/Insufficiency</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Prolonged Ventilation</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Sleep Apnea</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <description>Perioperative, treatment only</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Vascular Disease</sub_title>
                <description>Non-perioperative</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pulmonary or Vascular Emboli</sub_title>
                <description>Non-perioperative</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <description>Non-perioperative</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <description>Non-perioperative</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Non-cardiac vascular surgery</sub_title>
                <description>Non-perioperative</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Other Vascular Condition (nonspecific)</sub_title>
                <description>Non-perioperative</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematology</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="117" subjects_affected="63" subjects_at_risk="96"/>
                <counts group_id="E2" events="68" subjects_affected="46" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <counts group_id="E1" events="97" subjects_affected="47" subjects_at_risk="96"/>
                <counts group_id="E2" events="73" subjects_affected="35" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Genital-urinary</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory/Pulmonary</sub_title>
                <counts group_id="E1" events="38" subjects_affected="32" subjects_at_risk="96"/>
                <counts group_id="E2" events="31" subjects_affected="22" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>An interim analysis indicated trial futility based on a primary endpoint. Enrollment was suspended in July, 2009. Study was terminated as of April, 2011 due to insufficient resources.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Kolber, General Manager, VP of Regulatory Affairs</name_or_title>
      <organization>Paracor Medical, Inc.</organization>
      <phone>408-734-6000</phone>
      <email>info@paracor.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

